Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental shift in the management of relapsed and refractory large B-cell lymphoma.However, our understanding of risk factors associated with non-response is still insufficient and the search for predictive biomarkers continues.Some parameters measurable on 18F-fluoro